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Background: Tat is a key HIV-1 virulence factor, which plays pivotal roles in virus gene expression, replication,
transmission and disease progression. After release, extracellular Tat accumulates in tissues and exerts effects on
both the virus and the immune system, promoting immune activation and virus spreading while disabling the host
immune defense. In particular, Tat binds Env spikes on virus particles forming a virus entry complex, which favors
infection of dendritic cells and efficient transmission to T cells via RGD-binding integrins. Tat also shields the
CCR5-binding sites of Env rendering ineffective virus neutralization by anti-Env antibodies (Abs). This is reversed by
the anti-Tat Abs present in natural infection or induced by vaccination.
Findings: Here we present the results of a cohort study, showing that the presence of anti-Tat Abs in asymptomatic
and treatment-naïve HIV-infected subjects is associated with containment of CD4+ T-cell loss and viral load and with
a delay of disease progression. In fact, no subjects with high anti-Tat Ab titers initiated antiretroviral therapy during
the three years of follow-up. In contrast, no significant effects were seen for anti-Env and anti-Gag Abs. The increase
of anti-Env Ab titers was associated with a reduced risk of starting therapy only in the presence of anti-Tat Abs,
suggesting an effect of combined anti-Tat and anti-Env Abs on the Tat/Env virus entry complex and on virus
neutralization.
Conclusions: Anti-Tat immunity may help delay HIV disease progression, thus, targeting Tat may offer a novel
therapeutic intervention to postpone antiretroviral treatment or to increase its efficacy.
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The HIV-1 Tat protein plays essential roles in the virus life
cycle and in pathogenesis [1-9], representing a key HIV
virulence factor. Tat is produced very early upon infection
[1-5] and is released extracellularly [1,4,5]. By binding to
heparan sulfate proteoglycans with its basic region, extra-
cellular Tat accumulates in tissues [4] where it exerts ef-
fects on both the virus and the immune system [1-11],
making it an optimal target for an immune intervention
based on antibody (Ab) responses [12-14]. In particular,
extracellular Tat activates virus and cellular gene expression
and replication, increasing virus transmission to neighbor
cells [1,6-9,15,16]. Further, extracellular Tat binds Env
spikes forming a virus entry complex that favors infection
of dendritic cells (DC) and efficient transmission to T
cells, key target cells in primary infection that will later
constitute the virus reservoir [16]. This occurs by redirect-
ing virus entry from the canonical receptors to RGD-
binding integrins that Tat uses as receptors to enter DC
and other cells of the reticular-endothelial cell system
[16]. Of note, by binding the Env CCR5 co-receptor bind-
ing sites, Tat shields Env from anti-HIV Abs, thus inhibit-
ing virus neutralization by HIV sera, which, however, can
be restored and further increased by anti-Tat Abs either
present in natural infection or induced by vaccination
[16]. Notably, in natural HIV infection, anti-Tat Abs are
produced by only a small fraction of individuals [17,18],
while, in contrast, high Ab titers are produced against all
other viral products [19]. The reason for such a limited
anti-Tat Ab response is unclear. However, Tat has potent
immunoregulatory functions [10,11] and its capacity to
target, enter and induce DC maturation toward a preva-
lent Th1 response [10,11] may have implications for the
setting of the anti-HIV-1 immune response and in AIDS
pathogenesis. In fact, when present, anti-Tat Abs correlate
with the asymptomatic state and lower disease progression
[20-24]. In particular, a higher prevalence of anti-Tat AbsTable 1 Characteristics at baseline of the study participants
All subjects
(n = 61)
Age (years) 38 (32–42)
Male (%) 90.2
Female (%) 9.8
CD4+ (cells/μl) 544 (463–678)
CD4+ (%) 29.0 (25.0-34.0)
Viral load (log10 copies/ml) 4.2 (3.7-4.5)
Years from diagnosis of HIVb 1.3 (0.9-3.2)
HAART initiation since HIV+ (years)c 3.6 (2.9-5.0)
HAART initiation since study entry (months)c 22 (14–19)
Data are expressed as median with interquartile range (IQR).
aEight individuals became anti-Tat Ab-positive during follow-up; bBased on 52 indiv
cBased on data from 13 individuals, 4 anti-Tat Ab-positive with low and transient anhas been shown in asymptomatic and in non-progressors
HIV-1-infected individuals as compared to patients in
advanced disease or to fast progressors [20-24]. A cross-
sectional and longitudinal study, on 252 HIV-1 seroconver-
ters, with a median follow-up time of 7.2 years, indicated
that the presence of anti-Tat Abs is predictive of a slower
progression to AIDS or immunodeficiency [21]. Progres-
sion was faster in persistently anti-Tat Ab-negative than in
transiently anti-Tat Ab-positive subjects, whereas no pro-
gression was observed in individuals persistently anti-Tat
Ab-positive [21]. On the other hand, Tat vaccination in
monkeys can prevent or control infection with pathogenic
SHIV [25], and this correlates with Tat-specific Abs [12,26].
Thus, anti-Tat Abs may represent a predictive biomarker
of a slower progression to AIDS.
The effects of anti-Tat Abs on the immunological,
virological and clinical outcome of HIV-infected subjects
were assessed in a prospective observational study (ISS
OBS T-003, ClinicalTrials.gov NCT01029548) conducted
in asymptomatic drug-naïve HIV-infected adult volun-
teers enrolled in eight clinical centers in Italy. The study
was approved by the local Ethics Committees and all pa-
tients signed the informed consent prior to enrollment.
The study population consisted of 61 individuals, with
CD4+ T-cell counts ≥400/μl and levels of plasma
viremia ≤100,000 copies/ml, enrolled between 2008 and
2011, and followed for 42 months with visits every
3 months. The median follow-up was 24 months. The
characteristics at baseline of the study participants are
shown in Table 1.
Determination of anti-Tat Abs and plasma viral load
were performed by a centralized laboratory [13,14].
Anti-Tat Abs as well as anti-Env and anti-Gag IgG were
assessed by ELISA as previously described [19,21], using
100 ng of Tat or gp120 or p55 Gag/well, respectively. Ab
titers equal or higher than 25 for IgM and IgA, or 100
for IgG were considered positive.Anti-Tat Ab-positivea Anti-Tat Ab-negative
(n = 20) (n = 41)
38 (32–43) 38 (32–41)
95.0 87.8
5.0 12.2
546 (500–702) 541 (454–640)
29.0 (25.0-33.0) 28.5 (25.5-34.5)
4.2 (3.7-4.6) 4.2 (3.9-4.4)
1.0 (0.7-4.0) 1.6 (1.0-2.7)
3.6 (3.2-5.4) 3.5 (2.6-5.0)
30 (28–31) 17 (13–22)
iduals.
ti-Tat Abs (3 IgM and 1 IgG) and 9 anti-Tat Ab-negative.
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AmpliPrep/COBAS TaqMan HIV-1 Test, version 2.0.
CD4+ T-cell counts were performed at each clinical site
according to standard national laboratory measurements.
Statistical analyses were carried out at two-sided with a
0.05 significance level, using SAS® software, version 9.2.
Of the 61 subjects enrolled in the study, 20 (32.8%)
were anti-Tat Ab-positive. Eleven of these had median ti-
ters of 600 for IgG, 25 for IgM and 100 for IgA, which
persisted for the entire study (Table 2). These individuals
were termed “high” anti-Tat Ab-positive subjects. The
other 9 patients had anti-Tat Ab titers of 100 for IgG or
25 for IgM, and no IgA (Table 2); 4 of these subjects had
persistent Abs, whereas 5 had transient Abs (alternately
negative and positive). These were defined as “low” anti-
Tat Ab-positive subjects. Twelve subjects were anti-Tat
Ab-positive at study entry, while 8 individuals developed
Abs during follow-up (between months 3 and 21), 2 pa-
tients with high and 6 with low anti-Tat Abs, respect-
ively. The median anti-Env and anti-Gag IgG titers were
higher in high anti-Tat Ab-positive subjects as compared
to individuals with low or no Abs (Table 2). The baseline
demographic and clinical characteristics were com-
parable between subjects with or without anti-Tat Abs
(Table 1).
Of the 61 subjects, 13 started the highly active anti-
retroviral therapy (HAART) during follow-up, 1 for con-
comitant diseases, 1 for high viral load, 4 for low CD4+
T-cell counts and 7 for both low CD4+ T cells and high
viral load. The median values of CD4+ T cells and viral
load at HAART initiation were 364 cells/μl and 136,000
copies/ml, respectively. Of these patients, 9 were anti-
Tat Ab-negative at study entry and remained negativeTable 2 Anti-Tat, anti-Env and anti-Gag antibody responses.
High anti-Tat Ab titers
(n = 11)
Anti-Tat Ab-positive (n, %)
IgM and IgG positive 3 (27%)
IgG and IgA positive 1 (9%)
IgM positive 0 (0%)
IgG positive 6 (55%)
IgA positive 1 (9%)
Anti-Env Ab-positive (n, %) 11 (100%)
Anti-Gag Ab-positive (n, %) 11 (100%)
Median titers (range)
IgM anti-Tat 25 (25–25)
IgG anti-Tat 600 (200–12800)
IgA anti-Tat 100 (25–200)
IgG anti-Env 12,800 (800–51,200)
IgG anti-Gag 102,400 (4,000-2,457,600)during follow-up, while the other 4 patients had low and
transient anti-Tat Abs (3 IgM and 1 IgG) since month
15 or 18 of follow-up, respectively. Conversely, none of
the 11 subjects with high anti-Tat Abs started HAART.
The cumulative probability to remain naive to therapy
was higher in the anti-Tat Ab-positive than in the anti-
Tat Ab-negative subjects (Figure 1A), and this difference
was statistically significant when subjects with high anti-
Tat Ab titers were compared with individuals with no or
low anti-Tat Ab titers (Figure 1B). In particular, high
anti-Tat Ab-positive subjects showed no progression for
the entire follow-up (42 months), whereas the median
time to HAART was 30 months and 17 months for pa-
tients with low or no anti-Tat Abs, respectively.
The risk of starting therapy was 84% lower in anti-Tat
Ab-positive subjects as compared to anti-Tat Ab-negative
individuals. No effects were observed for anti-Gag IgG
titers, whereas 81% lower risk was detected with the in-
crease of anti-Env IgG titers, but only in the presence of
anti-Tat Abs, and the effect was lost in anti-Tat Ab-
negative subjects (Table 3).
A longitudinal analysis of the yearly changes of CD4+
T-cell counts and viral load was then performed for the
48 subjects who remained naive to therapy during the
study. The results showed a significant containment of
CD4+ T-cell loss and of plasma viral load increases in
anti-Tat Ab-positive subjects during the three years of
follow-up, as compared to anti-Tat Ab-negative subjects
(Figure 1C-D).
CD4+ T-cell counts and viral load were also analyzed
over time by applying a random coefficient model, show-
ing for anti-Tat Ab-negative individuals a decrease of 6
CD4+ T-cells/μl and an increase of 3.6% of viral load perLow anti-Tat Ab titers No anti-Tat Ab
(n = 9) (n = 41)
0 (0%) 0 (0%)
0 (0%) 0 (0%)
6 (67%) 0 (0%)
3 (33%) 0 (0%)
0 (0%) 0 (0%)
9 (100%) 41 (100%)
9 (100%) 41 (100%)
25 (25–25) <25
100 (100–100) <100
<25 <25
3,200 (400–12,800) 6,400 (800–38,400)
12,800 (1,600-819,200) 19,200 (200–3,276,800)
Figure 1 Kaplan-Meier curves, CD4+ T-cell number and viral load stratified by anti-Tat Abs. (A) Cumulative probability to remain naïve to
therapy according to the presence (n = 20) or absence (n = 41) of anti-Tat Abs, and (B) for subjects with high titers of anti-Tat Abs (n = 11) versus
subjects with low/no anti-Tat Abs (n = 50). (C) Baseline values and changes from baseline values of CD4+ T-cell counts and (D) viral load levels at
years 1, 2 and 3, according to the presence or absence of anti-Tat Abs, respectively, in subjects naïve to therapy (anti-Tat Ab-positive n = 16 year
1, n = 10 year 2, n = 10 year 3; anti-Tat Ab-negative n = 32 year 1, n = 17 year 2, n = 9 year 3). A longitudinal analysis for data arising from repeated
measures, adjusted for baseline values, was applied, using the generalized estimating equations method, where the measurements were assumed
to be multivariate normal. Data are presented as mean values with standard error.
Bellino et al. Retrovirology 2014, 11:49 Page 4 of 8
http://www.retrovirology.com/content/11/1/49month, respectively, while no significant changes were
detected in anti-Tat Ab-positive subjects (Figure 2A-B).
When anti-Env and anti-Gag Abs were included in the
analysis, the protective role of the presence of the anti-Tat Abs remained, while no significant effects were ob-
served for anti-Env or anti-Gag Abs (Table 4).
The results of the present study indicate a significant
association between the presence of anti-Tat Abs and a
Table 3 Risk of starting antiretroviral therapy
Parameters Hazard ratio 95% confidence limits P-value
All subjects (n = 52)
Anti-Tat Ab + vs Anti-Tat Ab- 0.16 0.03 – 0.84 0.0305
IgG anti-Env (log10 titers) 0.19 0.05 – 0.73 0.0148
IgG anti-Gag (log10 titers) 0.78 0.41 – 1.48 0.4573
Years from diagnosis of HIV 1.27 0.91 – 1.76 0.1631
CD4+ T cells/μl at baseline 1.00 0.99 – 1.00 0.3309
Viral load (log10 copies/ml) at baseline 2.53 0.75 – 8.52 0.1344
Anti-Tat Ab-negative subjects (n = 35)
IgG anti-Env (log10 titers) 0.41 0.06 – 2.67 0.3545
IgG anti-Gag (log10 titers) 1.57 0.27 – 9.04 0.6101
Years from diagnosis of HIV 1.00 0.46 – 2.20 0.9935
CD4+ T cells/μl at baseline 0.99 0.98 – 1.01 0.3445
Viral load (log10 copies/ml) at baseline 24.20 0.22 – 2671.23 0.1843
A Cox proportional hazards model with time-dependent repeated measurements was used to estimate the effects of the presence of anti-Tat Abs, or of anti-Env
or anti-Gag IgG titers on the risk of starting HAART, after adjusting for years from HIV diagnosis, CD4+ T cells and viral load at baseline. Anti-Env and anti-Gag Abs
were assessed at baseline and at 6, 18 and 36 months.
Figure 2 Changes over time of CD4+ T-cell number and viral load by anti-Tat Abs in individuals naïve to therapy. (A) CD4+ T-cell counts
and (B) viral load in subjects who remained naive to therapy were analyzed over time, according to the presence or absence of anti-Tat Abs, by
applying a random-effect regression model. The decrease from baseline of CD4+ T cells/μl was −1.1 (95% CI −3.7; 1.5) per month in the anti-Tat
Ab-positive subjects and −5.9 (95% CI −8.7; −3.1, p < 0.0001) per month in the anti-Tat Ab-negative individuals, respectively. The difference
between the coefficients of regression was statistically significant (p = 0.0060). Similarly, the increase of viral load was 0.003 log10 copies/ml (95%
CI −0.004; 0.010) per month in anti-Tat Ab-positive patients and 0.015 (95% CI 0.009; 0.022, p < 0.0001) per month in anti-Tat Ab-negative subjects,
respectively. The difference between the slopes was statistically significant (p = 0.0105). All longitudinal samples from 48 individuals were included
in the analysis.
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Table 4 Changes from baseline of CD4+ T cells and viral load by a longitudinal analysis.
Parameters Estimate 95% confidence limits P-value
CD4+ T cells/μl
Change per month in Anti-Tat Ab+ −1.6 −6.2; 3.0 0.4768
Change per month Anti-Tat Ab– −8.9 −13.8; −3.9 0.0011
IgG anti-Env (log10 titers) anti-Tat Ab+ 133.4 −130.0; 396.8 0.3070
IgG anti-Env (log10 titers) anti-Tat Ab– 150.0 −40.7; 340.6 0.1178
IgG anti-Gag (log10 titers) anti-Tat Ab+ −15.6 −141.6; 110.5 0.8014
IgG anti-Gag (log10 titers) anti-Tat Ab– −56.0 −177.8; 65.9 0.3533
Viral load (log10 copies/μl)
Change per month in Anti-Tat Ab+ 0.005 −0.007; 0.018 0.3898
Change per month Anti-Tat Ab– 0.011 0.001; 0.021 0.0401
IgG anti-Env (log10 titers) anti-Tat Ab+ 0.26 −0.64; 1.16 0.5560
IgG anti-Env (log10 titers) anti-Tat Ab– 0.08 −0.67; 0.83 0.8249
IgG anti-Gag (log10 titers) anti-Tat Ab+ −0.19 −0.57; 0.18 0.3006
IgG anti-Gag (log10 titers) anti-Tat Ab– −0.15 −0.55; 0.26 0.4632
Multivariate analysis for repeated measures of longitudinal samples from 41 individuals (random-effect regression model). Anti-Env and anti-Gag Abs were
assessed at baseline and at 6, 18 and 36 months.
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titers was associated with a lower risk of starting
HAART only in the presence of anti-Tat Abs, suggesting
that anti-Tat and anti-Env Ab combined have increased
HIV neutralizing effects by blocking the Tat/Env com-
plex formation and virus entry, as shown earlier both
in vitro and in vivo [16,26]. Thus both anti-Tat and anti-
Env Abs appear to be required to efficiently counteract
HIV disease progression. In contrast, no significant ef-
fects of anti-Env or anti-Gag Ab titers were observed on
CD4+ T-cell counts and viral load in patients naive to
therapy with or without anti-Tat Abs. Overall, anti-Tat
Ab-positive patients showed a remarkable preservation
of CD4+ T cells and containment of viral load for the en-
tire follow-up (3 years), and no individuals with high levels
of anti-Tat Abs initiated HAART during follow-up.
Based on this notion, phase I-II trials of therapeutic
immunization with the Tat protein have been conducted
in HIV-infected asymptomatic or HAART-treated patients
in Italy (ISS T-001, ClinicalTrials.gov NCT00505401 and
ISS T-002 ClinicalTrials.gov NCT00751595, respectively)
[13,14] and a phase II trial is ongoing in South Africa in
patients under HAART (ISS T-003, ClinicalTrials.gov
NCT01513135). The results from these studies indicate
that the Tat vaccine is safe and immunogenic, since it in-
duced high titers of anti-Tat Abs with a remarkable per-
sistence over time and with characteristics similar to those
of the subjects with high anti-Tat Abs described here.
More importantly, Tat vaccination in HAART-treated sub-
jects increased CD4+ T-cell number, restored functional
CD4+ and CD8+ subsets (i.e. central memory T cells),
increased B and NK cell numbers, and progressively re-
duced HIV proviral DNA [14, Ensoli F. et al., manuscriptsubmitted]. These data suggest that the induction of an
anti-Tat humoral immune response may effectively help
delay, and possibly counteract HIV disease progression
and antiretroviral treatment initiation.
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